OP22: The risk of cancer in pediatric-onset immune-mediated inflammatory diseases – a nationwide Danish study from 1980-2018.ECCO’23 Copenhagen 2023
OP23: Asymptomatic inflammatory bowel disease diagnosed during the colorectal cancer population screening in CataloniaECCO’23 Copenhagen 2023
OP25: Prevalence of IBD in the Netherlands: development and validation of machine learning models for administrative dataECCO’23 Copenhagen 2023
OP26: Impact of telemonitoring with TECCU on the management of Inflammatory Bowel Disease in Spain: a GETECCU clinical trialECCO’23 Copenhagen 2023
OP27: Benefits of paediatric to adult transition program in Inflammatory Bowel Disease: The BUTTERFLY study of GETECCUECCO’23 Copenhagen 2023
OP28: Children and young adults with inflammatory bowel disease have an increased incidence and risk of developing mental health conditions: a UK population-based cohort studyECCO’23 Copenhagen 2023
OP29: Peri-natal exposure to parental Crohn’s disease is associated with impaired gut barrier, microbiome composition differences and increased risk of Crohn’s diseaseECCO’23 Copenhagen 2023
OP32: The gut virome-colonizing Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivoECCO’23 Copenhagen 2023
OP33: Results of a randomised controlled trial to evaluate Interleukin 1 blockade with anakinra in patients with acute severe ulcerative colitis (IASO)ECCO’23 Copenhagen 2023
OP34: Enteral Nutrition Compared with Steroids in Children with Crohn’s Disease – In Israel: a nationwide study from the epi-IIRNECCO’23 Copenhagen 2023
OP35: Efficacy and safety outcomes up to ~4 years of treatment with filgotinib 200 mg among patients with Ulcerative Colitis: Results from the SELECTIONLTE studyECCO’23 Copenhagen 2023
OP38: Modulation of the septin cytoskeleton ameliorates intestinal fibrogenesisECCO’23 Copenhagen 2023
OP39: Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UCECCO’23 Copenhagen 2023
OP40: PRA023 Demonstrated Efficacy and Favorable Safety as Induction Therapy for Moderately to Severely Active UC: Phase 2 ARTEMIS-UC Study ResultsECCO’23 Copenhagen 2023
SCI01: Treatment sequencing in moderate to severe CD: Who’s first and who’s last?ECCO’23 Copenhagen 2023
SCI02: Treatment sequencing in moderate to severe UC: Who’s first and who’s last?ECCO’23 Copenhagen 2023
SCI03: Treatment of CD postoperative recurrence: Medical, endoscopic or surgical?ECCO’23 Copenhagen 2023